Ipsen’s active partnership policy underpins internal R&D, from fundamental research through to clinical development.
An active partnership policy
Partnerships are crucial to continued success. The in-house work by Ipsen’s R&D department is supported by an active partnership policy, managed by the Scientific Affairs team. Our research collaborations range from fundamental research right through to clinical development.
Our partnership philosophy is based on the knowledge that even though Ipsen’s R&D employees are leading experts in their fields, they represent only a tiny fraction of the expertise available in our specialist fields around the world. We know it is essential to combine the skills and projects in our own labs with those of other leading companies and organizations in medical and pharmaceutical R&D.
At the research stage, Ipsen has established academic collaborations with Massachusetts General Hospital, the Dana-Farber Cancer Institute and the Harvard Medical School in Boston, Biostar in Singapore, and Inserm in France.
The Group is a long-term partner – since 2008 – of the prestigious Salk Institute (La Jolla, California), which conducts fundamental research in our fields of interest. Partnerships have also been established with pioneering biotech companies, offering access to innovative and promising technologies to discover potential new drugs.